Primary Localized Cutaneous Amyloidosis: A Systematic Treatment Review.

Till Weidner, Tanja Illing, Peter Elsner

Journal: American journal of clinical dermatology 2018;18(5):629-642

PMID: 28342017

Abstract

BACKGROUND

Primary localized cutaneous amyloidosis (PLCA) is characterized by extracellular deposition of heterogenic amyloid proteins in the skin without systemic involvement. Lichen amyloidosis, macular amyloidosis, and (primary localized cutaneous) nodular amyloidosis are different subtypes of PLCA.

OBJECTIVE

The aim of this study was to review the current reported treatment options for PLCA.

METHODS

This systematic review was based on a search in the PubMed database for English and German articles from 1985 to 2016.

RESULTS

Reports on the treatment of PLCA were limited predominantly to case reports or small case series. There were a few clinical trials but these lacked control groups. A variety of treatment options for PLCA were reported including retinoids, corticosteroids, cyclophosphamide, cyclosporine, amitriptyline, colchicine, cepharanthin, tacrolimus, dimethyl sulfoxide, vitamin D analogs, capsaicin, menthol, hydrocolloid dressings, surgical modalities, laser treatment, and phototherapy.

CONCLUSION

No definitive recommendation of preferable treatment procedures can be made based on the analyzed literature. Randomized controlled trials are needed to offer patients an evidence-based therapy with high-quality standardized treatment regimens for PLCA.

Address: Department of Dermatology, University Hospital Jena, Erfurter Straße 35, Jena, 07743, Germany. [email protected].; Department of Dermatology, University Hospital Jena, Erfurter Straße 35, Jena, 07743, Germany.

Link outs

Free resources

Other Literature Sources:

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.